[Ocular graft versus host disease]

Ocular graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly an inflammatory and destructive ocular surface disease with increasing incidence. It not only leads to a reduced quality-of-life but can also impair vision and in severe cases lead to blindness. The occurrence of GVHD can lead to a severe, often refractory disorders of the ocular surface, which is associated with chronic inflammation. The occurrence of corneal involvement is a major problem. The establishment of comprehensive care structures and individually adapted stage-appropriate treatment in interdisciplinary collaboration with colleagues in hemato-oncology is therefore of particular importance.